AstraZeneca’s Covid-19 shot, developed by Oxford University, has resulted in reports of rare blood clots with low platelet levels that occur more commonly in younger adults. Such a step would further delay any rollout of the British drugmaker’s shots in the United States, according to the report, which cited people familiar with the matter. Last week, AstraZeneca said it was working as fast as possible to compile data on its Covid-19 vaccine to apply for US approval. The White House said late in April that the United States would start to share up to 60 million doses of AstraZeneca’s coronavirus vaccine with other countries over the next few weeks. AstraZeneca’s Covid-19 shot, developed by Oxford University, has resulted in reports of rare blood clots with low platelet levels that occur more commonly in younger adults.

Source: Wall Street Journal May 08, 2021 04:34 UTC